VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Condition: Nipah Virus Infection Intervention: Biological: mRNA -1215 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Clinical Trials | Infectious Diseases | Nipah Virus | Research | Vaccines